Imaging the Dopamine Systems in Bulimia Nervosa

Eating Disorders Clinical Trial

Official title:

Imaging the Dopamine Systems in Bulimia Nervosa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01493362
• Other study ID #: #5175
• Secondary ID: R01MH079397
• Status: Completed
• Phase: N/A
• First received: December 14, 2011
• Last updated: August 14, 2014
• Start date: January 2008
• Est. completion date: December 2013

Study information

• Verified date: November 2011
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

This study will use positron emission tomography imaging to investigate the dopamine systems in people with bulimia nervosa.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

Participants with BN:

• Meets DSM-IV criteria for BN

• Sufficiently medically and psychiatrically stable to participate in research

Health Control Participants:

• No current or past psychiatric illness

• Between 80% and 120% of ideal body weight

Exclusion Criteria:

All participants:

• Current use of psychotropic medication such as anti psychotics or antidepressants

• Pregnant or breastfeeding

• history of substance abuse

• Significant medical illness

• High blood pressure (resting systolic blood pressure greater than 150mmHg and diastolic blood pressure greater that 90 mmHg)

• Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV

• Metal implants or paramagnetic objects contained within the body that may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to specified reference book guidelines

• Exposed to radiation in the workplace or has had a nuclear medicine procedure during the 1 year before study entry

• Previous adverse reaction to psycho stimulants

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Bulimia
• Bulimia Nervosa
• Eating Disorders

Locations

Country	Name	City	State
United States	New York State Psychiatric Institute	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
New York State Psychiatric Institute	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	D2 receptor density		Measured at baseline	No
Primary	DA release in the striatum		Measures after Mythlyphenidate challenge	No